COLL
Collegium Pharmaceutical, Inc.
COLL's fundamentals are mixed, but it looks expensive: trading at 25x earnings, above its usual 19x. Analysts expect earnings to hold roughly steady, though they disagree widely on how much.
COLL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Strong |
COLL's cash flow and balance sheet are currently strong, and its revenue and profitability are stable.
COLL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.5x | $24.95 | — |
| Cheap | 13x | $12.57 | -50% |
| Fair | 19x | $19.08 | -24% |
| Current | 25x | $24.95 | — |
| Expensive | 34x | $33.57 | +35% |
Historical ranges are pointers, not guarantees.
COLL's PE is in its expensive range at 25x. On analysts' estimates for next year's earnings, today's price would be 3.5x, in its cheap range.
COLL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect COLL's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
COLL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.07 | +607% |
| Q3 2026 | $1.00 | -38% |
| Q2 2026 | $1.24 | +19% |
| Q1 2026 | $2.04 | +67% |
| Q4 2025 | $1.71 | -8.1% |
| Q3 2025 | $1.61 | -31% |
| Q2 2025 | $1.04 | -60% |
| Q1 2025 | $1.22 | -49% |
| Q4 2024 | $1.86 | +58% |
COLL's earnings per share have fallen from their peak: $1.00 over the past year, against $2.72 in mid-2021.
COLL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $216.3M | +3.3% |
| Q2 2026 | $199.9M | +6.3% |
| Q1 2026 | $193.5M | +8.9% |
| Q4 2025 | $205.4M | +13% |
| Q3 2025 | $209.4M | +31% |
| Q2 2025 | $188M | +29% |
| Q1 2025 | $177.8M | +23% |
| Q4 2024 | $181.9M | +22% |
COLL's revenue has grown year over year for 18 quarters in a row: $216M last quarter, up 3.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -16 points |
| Q2 2026 | 1.9% | -17 points |
| Q1 2026 | 16% | +3.8 points |
| Q4 2025 | 30% | +8.6 points |
| Q3 2025 | 30% | +7.8 points |
| Q2 2025 | 19% | -14 points |
| Q1 2025 | 12% | -22 points |
| Q4 2024 | 21% | -20 points |
COLL's operating margin was 13% last quarter, down 16 points from the same quarter a year ago.
COLL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $86.3M | +10% |
| Q2 2026 | $70.8M | -2.1% |
| Q1 2026 | $56.8M | +4.1% |
| Q4 2025 | $122.4M | +46% |
| Q3 2025 | $78.3M | +$87.5M |
| Q2 2025 | $72.4M | +7.8% |
| Q1 2025 | $54.6M | -11% |
| Q4 2024 | $84.1M | +15% |
COLL generated $336M in free cash flow over the past year, up 16% from the year before.
COLL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +20% | +6.7M shares |
| 1 year | -0.8% | -329K shares |
| 3 years | -7% | -2.9M shares |
| 5 years | +7.9% | +2.8M shares |
| Available history | +16% | +5.5M shares |
COLL has 39M diluted shares, down 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | $25M |
| Q3 2024 | — |
| Q4 2023 | $25M |
| Q4 2022 | $7.6M |
| Q4 2021 | $32.3M |
COLL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.6x | Very low |
COLL's net debt is less than a year of its operating earnings (EBITDA).
COLL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.8 | Neutral |
| Stochastic | 25.6 | Neutral |
COLL's weekly RSI is 39 (neutral) and its Stochastic is 26 (neutral).
COLL PE vs Healthcare Sector
| Metric | COLL | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 26x | 3.5% below |
| PE % | 66 | 29 | 37 pts above |
COLL is trading at 25x earnings, in line with the Healthcare sector's median of 26x.
COLL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.2 | 7.5% above |
| 20 week MA | $27.2 | 8.2% below |
| 50 week MA | $34.7 | 28% below |
| 100 week MA | $33.7 | 26% below |
| 200 week MA | $31.6 | 21% below |
COLL has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 21% below its 200-week average.
COLL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.0 | $18.6 | -12% |
| 2021 | $18.6 | $19.5 | +4.9% |
| 2022 | $19.5 | $23.0 | +18% |
| 2023 | $23.0 | $30.8 | +34% |
| 2024 | $30.8 | $29.1 | -5.4% |
| 2025 | $29.1 | $49.8 | +71% |
| 2026 YTD | $49.8 | $25.0 | -50% |
COLL is down 50% so far in 2026, after finishing higher in four of the previous six years.